Skip to main content

Starpharma (ASX: SPL) — Company Overview, News & Financial Data

Starpharma logo
SPL Starpharma
Starpharma primary media
Company profile

Starpharma

About

Explore Australia companies

Starpharma is a biotechnology company headquartered in Australia that develops and commercializes dendrimer-based pharmaceutical products and drug delivery technologies. Operating from Abbotsford, Victoria, the company utilizes its dendrimer platform to design nanoparticle formulations intended to improve the efficacy, safety, and delivery of small molecules, radiopharmaceuticals, and biological therapeutics, particularly in oncology. Its portfolio includes clinical-stage candidate compounds, commercialized topical gels for women's health, and antiviral nasal sprays distributed globally. Starpharma also engages in licensing and co-development partnerships with international pharmaceutical and biotechnology organizations to apply its nanomedicine capabilities across candidate drug pipelines.

Snapshot

Public AUOwnership
1996Year founded
11–50Employees
Melbourne, AustraliaHead office
Loading Map...
Global footprint

Operations

All Locations
Australia
Melbourne, AU

Products and/or services of Starpharma

  • Drug Delivery Technology: Proprietary dendrimer-based drug delivery technology engineered to improve the solubility, pharmacokinetic profile, therapeutic index, and precision targeting of small molecule and biological pharmaceutical compounds across oncology and various major therapeutic areas.
  • Oncology Chemotherapy Formulations: Clinical-stage dendrimer-enhanced chemotherapeutic drug candidates developed to improve efficacy, extend plasma half-life, and reduce systemic toxicities compared to standard therapies when treating patients with advanced solid tumors and refractory cancers.
  • Targeted Radiopharmaceuticals: Research and development of radiotherapeutic dendrimer conjugates that bind radioisotopes to targeted delivery vehicles, enabling precise delivery of localized radiation directly to specific receptors expressed on cancer cells in solid tumors.
  • Topical Women's Health Products: Commercialized dendrimer-based gel formulations developed for management of bacterial vaginosis and reduction of pathogenic risk, distributed globally through regional pharmaceutical distribution agreements and retail commercial partnerships in multiple international markets.
  • Respiratory Antiviral Nasal Sprays: Over-the-counter nasal spray products containing broad-spectrum virucidal dendrimers designed to physically trap and neutralize respiratory viruses in the nasal cavity, providing localized barrier protection against airborne viral infections in international consumer markets.
  • Pharmaceutical Development Partnerships: Collaborative drug development and licensing arrangements with major global pharmaceutical companies to apply proprietary dendrimer delivery systems to partner compounds, enabling customized formulation development, preclinical evaluation, and commercial licensing opportunities.

Starpharma executive team

  • Ms. Cheryl Maley B.Sc., M.B.A.CEO, MD & Director
  • Mr. Justin CahillCFO & Company Secretary
  • Ms. Sindy SmithCommunications & Investor Relations Manager
  • Ms. Miranda SowdenDirector of People & Culture